Detalhe da pesquisa
1.
Clinical evidence for efficacy of pembrolizumab in MSI-H and TMB-H advanced solid tumor: results from three cancer centers in China.
Cancer Immunol Immunother
; 73(4): 74, 2024 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38451314
2.
Clinical activity of pembrolizumab with or without chemotherapy in advanced pulmonary large-cell and large-cell neuroendocrine carcinomas: a multicenter retrospective cohort study.
BMC Cancer
; 23(1): 443, 2023 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37189075
3.
Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study.
BMC Cancer
; 22(1): 952, 2022 Sep 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36064386
4.
A Burning External Colon Cancer Patient With Diffuse Miliary Peritoneal Metastases.
Am J Gastroenterol
; 116(4): 632, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33982924
5.
First-in-human phase I study of BEBT-109 in previously treated EGFR exon 20 insertion-mutated advanced non-small cell lung cancer.
Med
; 5(5): 445-458.e3, 2024 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38521070
6.
Clinical treatment patterns, molecular characteristics and survival outcomes of ROS1-rearranged non-small cell lung cancer: A large multicenter retrospective study.
Lung Cancer
; 192: 107827, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38795459
7.
Intracranial activity of first-line immune checkpoint inhibitors combined with chemotherapy in advanced non-small cell lung cancer.
Chin Med J (Engl)
; 136(12): 1422-1429, 2023 Jun 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37195128
8.
Dynamic cytokines signature predicts survival outcome from severe Immune-related hepatitis with PD-1/PD-L1 blockade in lung cancer.
Lung Cancer
; 184: 107350, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37659241
9.
Investigation on the survival implications of PD-L1 expression status in ALK- rearranged advanced non-small cell lung cancer treated with first-line crizotinib.
Lung Cancer
; 167: 58-64, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35405360
10.
Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancer.
Commun Med (Lond)
; 2(1): 137, 2022 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36352254
11.
A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab.
Lung Cancer
; 143: 55-59, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32208297
12.
ALK-rearranged lung adenocarcinoma resistant to alectinib with cauliflower gingival metastasis responds to brigatinib.
Thorac Cancer
; 13(7): 1095-1097, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35150066
13.
Brigatinib After Progression From Alectinib or Crizotinib: Paving the Way for Treatment Sequencing of ALK Inhibitors in ALK-Positive NSCLC.
J Thorac Oncol
; 16(3): 349-351, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33641716